Up to 20%
of breast cancers have an underlying genetic risk that cannot be detected by single-gene analysis (e.g., BRCA1 / BRCA2).³
Breast Cancer Integrated Risk
Combines genetic and clinical factors to calculate personalized, absolute 5-year and remaining lifetime risk of developing breast cancer — for individuals who do not have single gene-driven hereditary breast cancer risk.
Why it matters
Risk the standard workup does not capture
Up to 95%
of women* do not have a single-gene breast cancer condition but may have genetic risk factors detectable by this test.¹
Up to 6%
of women* classified as low-risk by a standard risk tool were reclassified as high-risk by Integrated Risk — increasing change of eligibility for preventive recommendations.
1. Garber JE, Offit K. Hereditary Cancer Predisposition Syndromes. J Clin Oncol. 2005;23:276–292. 2. Tshiaba P, et al. Integration of a Cross-Ancestry Polygenic Model With Clinical Risk Factors Improves Breast Cancer Risk Stratification. JCO Precis Oncol. 2023;7:e2200447. 3. Wendt C, Margolin S. Acta Oncologica. 2019;58(2):135–146. *MyOme recognizes and respects the diversity of gender identities. For the purposes of this webpage, "women" refers to individuals assigned female at birth.
HOW AN INTEGRATED RISK SCORE IS CALCULATED
Genetics integrated with clinical risk factors
Genetic analysis covers more than one million markers, integrated with the following clinical risk factors.
Genetic risk factors analyzed by WGS:
- >1M disease risk factors identified in large GWAS studies of patients with breast cancer
- Thousands of ancestry markers, producing a cross-ancestry PRS that accurately stratifies risk across diverse populations
Clinical risk factors analyzed*:
- Current age
- Age at menarche
- Age at first live birth
- Menopausal status
- Hormone therapy use and duration
- Body mass index
- Breast biopsy history
- Family history of breast cancer (both lineages)
- Breast density
*Based on those inputs included in the Tyrer-Cuzick clinical model
Who it's for
Eligibility, turnaround times, and sample types
Eligibility
Individuals assigned female at birth, aged 18–84. Individuals with a confirmed pathogenic variant in a breast cancer predisposition gene, or with a personal history of breast cancer, are not eligible.
Turnaround times
From samples received, most results are delivered in 5 to 6 weeks. Follow-up testing or re-requisitions for existing MyOme patients are typically completed in under 2 weeks, often within a few days.
Sample Types Accepted
- Blood
- Buccal (cheek swab)
Test codes
Atlas Cancer PlusPR41003
Atlas Cancer SelectPR42009
Turnaround times are estimates and begin once samples are processed at MyOme. They may be extended in cases outside MyOme's control, including delays related to confirmation testing or other unforeseen circumstances.
Ordering
Two Ordering Options
This test can be ordered as part of the Atlas Cancer Plus or Atlas Cancer Select offerings, depending on your needs.
Atlas Cancer Plus
Leverages whole-genome sequencing for comprehensive insights across coding and non-coding regions.
View the technical one-pagerAtlas Cancer Select
Uses high-coverage exome plus low-coverage whole-genome sequencing — a cost-effective option for preventative health decisions.
View the technical one-pagerInterpreting results
Implications for prevention
Guidelines recommend additional risk reduction strategies for individuals at increased risk to develop breast cancer. Those with a >20% lifetime risk should consider an annual breast MRI alongside mammography.¹
Those with a >1.7% 5-year risk should consider endocrine risk-reducing medications based on age and menopause status.² Providers should consider a patient’s personal and family history when determining the appropriate screening and prevention strategies.
Representative report page — not an actual patient result.
Important considerations
What this test can and cannot tell you
This test is a screening tool, not a diagnostic test.
This test does not detect high-risk variants linked to monogenic conditions.
The Integrated Risk test is intended as a screening tool — some people with a high risk score will not develop breast cancer and some with a low risk score will.
Map your risk, guide lifelong health.
We're here at every step — from ordering and sample collection to interpreting results with your patients.